Author

Luca Menichetti

Istituto di Fisiologia ClinicaORCID 0000-0002-3293-9616Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Alessandra FloriiD· 1 shared Alice ChiodiiD· 1 shared Arianna ConsiglioiD· 1 shared Azhar AliiD· 1 shared Chiara CavalliniiD· 1 shared Elena LevantiniiD· 1 shared Eleonora VanniniiD· 1 shared Elisa De SantisiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandra FloriORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GABAergic Circuit Activation Induces a Therapeutically Responsive State for anti-PD-L1 Immunotherapy in Glioblastoma

M Scalera, Elisa De Santis, Filippo Rossi, Nicolò Meneghetti, Lorenzo Amir Nemati Fard, Pasquale Miglionico, Francesco Raimondi, Alessandra Flori, Massimo Pasqualetti, Luca Menichetti, Soma Sengupta, Eleonora Vannini, Mario Costa

This study shows that activating GABAergic circuits with baclofen enhances the effectiveness of anti-PD-L1 immunotherapy in glioblastoma, leading to tumor regression and prolonged survival in mice.

bioRxiv · Aug 27, 2026 · PreprintCancer Biology

The two sides of resistance: aggressiveness and mitotic instability as the Achilles heel of Osimertinib-resistant NSCLC

Paolo Armanetti, Eva Cabrera San Millán, Raffaella Mercatelli, Chiara Cavallini, Alice Chiodi, Ettore Mosca, Arianna Consiglio, Nicola Losito, Luca Menichetti, Emilia Bramanti, Azhar Ali, Elena Levantini, Giorgia Maroni

This study identifies BMI1 as a driver of Osimertinib resistance in NSCLC by promoting mitotic instability and aggressiveness, and shows that targeting BMI1 with Unesbulin can suppress tumor growth.

bioRxiv · Sep 25, 2025 · PreprintCancer Biology